Trial News & Events
AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS)
- Phase 2 of AP-101 in sporadic ALS and mutant SOD1-ALS met its primary safety and tolerability endpoint
Sign Up Today! Bike the US for ALS- NEALS Ride
Bike the US for ALS – 30th Anniversary Ride
Ride. Support. Make an Impact.
We invite you to join us for a special fundraising ride as we commemorate 30 years of advancing ALS research and care through NEALS.
🚴♂️ September 18–24, 2025
📍 Route: GAP and C&O Trail (Pittsburgh, PA → Washington, D.C.)
🎯 Fundraising Goal: $5,000 per rider
Qalsody Conditionally Approved in Canada for ALS Linked to SOD1 Gene Mutations
QALSODY™ (tofersen injection) Receives Conditional Marketing Authorization from Health Canada as the First ALS Treatment Targeting a Genetic Cause
Groundbreaking Directive Ensures ALS Patients on Medicare Advantage Gain Access to Qalsody
The Centers for Medicare & Medicaid Services (CMS) has announced a first-of-its-kind directive requiring Medicare Advantage plans to approve coverage for Qalsody, a treatment for people living with genetic SOD1-ALS. This decision reflects the ALS Association’s commitment to ensuring that people living with ALS have access to promising ALS treatments without delay.
First Participant Enrolled in NIH-Funded Access for All in ALS Consortium
The Access for All in ALS Consortium (ALL ALS) announced the successful enrollment of the first participant..
Established in the autumn of 2023 with funding from the National Institutes of Health (NIH), ALL ALS is a multi-institutional effort, and aims to disrupt the ALS clinical research landscape using open science methods to build broadly accessible resources to advance ALS research. The consortium brings together research scientists from across the country, combining their efforts to collect clinical and biomarker data from people with ALS symptoms, asymptomatic individuals at risk of developing inherited forms of ALS, and control participants. The ALL ALS clinical and genomic data and biofluid collections will help researchers investigate the antecedents of ALS, its onset, progression, prognostication, and response to effective therapies.
